ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma. (22nd March 2011)

• Record Type: Journal Article
• Authors: Roulin, Didier; Demartines, Nicolas; Dormond, Olivier
• Is Part Of: Biochemical Society transactions. Volume 39:Number 2(2011)
• Page Start: 492
• Page End: 494
• Publication Date: 2011-03-22
• Subjects: ATP-competitive inhibitor -- hypoxia-inducible factor (HIF) -- mammalian target of rapamycin (mTOR) -- rapalogue -- renal cell carcinoma (RCC); Biochemistry -- Congresses; 572
• DOI: 10.1042/BST0390492
• Languages: English
• ISSNs: 0300-5127

Abstract

Abstract : Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment of advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and have been approved for the treatment of RCC. Recently, with the development of ATP-competitive inhibitors of mTOR, therapies targeting mTOR have entered a new era. Here, we discuss the biological relevance of blocking mTOR in RCC and review the mechanisms of action of rapalogues in RCC. We also advance some perspectives on the use of ATP-competitive inhibitors of mTOR in RCC.